Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety

Epilepsy Res. 2000 Jan;38(1):27-32. doi: 10.1016/s0920-1211(99)00063-7.

Abstract

Purpose: To evaluate the efficacy and safety of gabapentin (GBP) in partial epilepsy in children.

Methods: We performed a prospective open label add-on study in 52 children and adolescents (age 1.8-17.5 years, mean 11.1 years) with refractory partial seizures. Gabapentin was added to one other baseline drug and the efficacy was rated according to seizure type and frequency.

Results: The GBP dose ranged from 26 to 78 mg/kg per day (mean 52 mg/kg per day) and was well tolerated in most patients. The seizure frequency remained unchanged in 34 patients (65%). We saw a provocation of seizures in three children (6%). Initially 15 patients (29%) benefited from GBP: five (10%) with a seizure reduction of 50-74%, seven (13%) with a reduction of 75-99% and three (6%) became seizure free. All but three experienced a development of tolerance within the next weeks to months.

Conclusions: Although gabapentin seems also to be safe in children, the efficacy in refractory partial seizures was disappointing.

Publication types

  • Clinical Trial

MeSH terms

  • Acetates / adverse effects
  • Acetates / therapeutic use*
  • Adolescent
  • Amines*
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Child
  • Child, Preschool
  • Cyclohexanecarboxylic Acids*
  • Drug Resistance
  • Drug Therapy, Combination
  • Epilepsy / drug therapy*
  • Female
  • Gabapentin
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • gamma-Aminobutyric Acid*

Substances

  • Acetates
  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin